Jco precision oncology.

JCO Precision Oncology showcases high-quality, original documents where all submitted articles are peer reviewed to provide the best quality. The journal welcomes submissions from the research community where emphasis will be placed on the originality and the practical impact of the reported research.PURPOSE The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be drug targets. Results in a cohort of patients with non–small-cell lung cancer (NSCLC) with CDKN2A alterations treated with palbociclib are ...DOI: 10.1200/PO.18.00037 JCO Precision Oncology - published online July 23, 2018WebDOI: 10.1200/PO.20.00436 JCO Precision Oncology no. 5 (2021) 744-750. Published online May 3, 2021. Published online May 3, 2021. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression—A Case Report

JCO PO publishes controlled randomized clinical trials and other comparative studies in precision oncology. For randomized clinical trials and other comparative studies, authors should carefully follow the ICMJE and CONSORT statement guidelines. To produce consistent results, please refer to JCO PO 's CONSORT template.DOI: 10.1200/PO.20.00187 JCO Precision Oncology no. 4 (2020) 1163-1166. Published online September 29, 2020. PMID: 35050775. Targeted Therapy in BRAF p.K601E–Driven NSCLC: Case Report and Literature Review Felix C. Saalfeld, MD 1, 2. x. Felix C. Saalfeld. Search for articles by this author ...

PURPOSE The adoption of precision medicine (PMed) depends on the critical curation of data and interpretation of genomic results. Herein, we sought to study the effect of a coordinated multidisciplinary program to assess results in a community cancer center clinic. METHODS In a retrospective review from July 2018 to July 2021, we …JCO PO recognizes that a practice-changing manuscript may have undergone prior peer review by a highly regarded oncology or cancer research journal, but it was not accepted for publication for reasons of priority. Such papers may be more appropriate for an oncology specialty journal such as JCO PO. In that regard, JCO PO 's new program will ...

May 16, 2017 · Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision oncology knowledge base. Methods OncoKB annotates the ... Oct 6, 2022 · DOI: 10.1200/PO.22.00024 JCO Precision Oncology no. 6 (2022) e2200024. Published online October 6, 2022. PMID: 36201714 DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017By choosing this option you are agreeing to pay the article processing charge of $2,300 (Original Reports) or $792 (Case Reports). This will be billed after acceptance of your article. Open access requirements may vary depending on the source of funding for your submission. If you have questions regarding open access requirements, this guide to ...

DOI: 10.1200/PO.22.00509 JCO Precision Oncology no. 7 (2023) e2200509. Published online April 7, 2023. PMID: 37027812

24-hour private clinics and medical centers 49 Ambulatory surgery in Tashkent, in Uzbekistan 4 Analyses of blood by rubella - services 3 Analysis of allergy - services 7 …

DOI: 10.1200/PO.21.00283 JCO Precision Oncology no. 6 (2022) e2100283. Published online May 25, 2022. PMID: 35613412. Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an NTRK Oncogenic Fusion Anne Thorwarth, MD 1. x. Anne Thorwarth ...Nov 17, 2021 · Precision oncology relies on robust molecular analyses of patient samples and accurate interpretation of genomic sequencing and biomarker data. 1 Advances in genomic sequencing have made tumor genomic profiling a routine process in the clinical evaluation and treatment planning of patients with cancer. 2 The main objective is to provide a detailed characterization of a patient's neoplasm ... Professional English and Academic Editing Support. Submit to JCO PO. View/Change User Info. Institutions and Librarians. Subscribe to this Journal. Journal of Clinical Oncology. JCO Oncology Practice. JCO Global Oncology. JCO Clinical Cancer Informatics. DOI: 10.1200/PO.16.00066 JCO Precision Oncology - published online June 27, 2017WebDOI: 10.1200/PO.18.00028 JCO Precision Oncology - published online October 19, 2018WebPrecision oncology relies on robust molecular analyses of patient samples and accurate interpretation of genomic sequencing and biomarker data. 1 Advances in genomic sequencing have made tumor genomic profiling a routine process in the clinical evaluation and treatment planning of patients with cancer. 2 The main objective is to …Web

Soft boiled eggs are a delicious and versatile dish that can be enjoyed for breakfast, lunch, or dinner. Cooking the perfect soft boiled egg requires precision and attention to detail.DOI: 10.1200/PO.21.00141 JCO Precision Oncology no. 5 (2021) 1270-1280. Published online August 11, 2021. Published online August 11, 2021. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer TypesDOI: 10.1200/PO.19.00115 JCO Precision Oncology - published online October 23, 2019 Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program Michael J. Pishvaian, MD, PhD 1, 2. x. Michael J. Pishvaian. Search for articles …WebJan 6, 2022 · An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry. Le Tourneau et al. Published online: August 8, 2022. PURPOSE HER2 is a critical gene that drives various solid tumors in addition to those of breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC). Overexpression, amplification, and point mutations in HER2 have been described in patients with NSCLC; however, the potential roles of these alterations remain unclear. METHODS We summarize the evidence regarding the ...PURPOSE HER2-altered non–small-cell lung cancer (NSCLC) represents a diverse subgroup, including mutations, amplifications, and overexpression. However, HER2 exon 20 insertion mutations are emerging as a distinct molecular subtype with expanding therapeutic options. We describe the molecular epidemiology and genomic features of …Web

The Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ...DOI: 10.1200/PO.20.00110 JCO Precision Oncology no. 4 (2020) 823-824. Published online July 16, 2020. PMID: 35050756. Remarkable Response to Erdafitinib in Metastatic Lung Adenocarcinoma With FGFR Fusion Samuel A. Urrutia Argueta, MD 1. x. Samuel A. Urrutia Argueta. Search for articles by this author ...

This confidence in precision oncology in the absence of definitive RCTs has resulted in creative RWE solutions to the marketplace demand (eg, TAPUR [Targeted Agent and Profiling Utilization Registry] …Standardizing Brain Magnetic Resonance Imaging using Generative Adversarial Networks: A Multisite Study Approach. Kulkarni, Chaitanya; Dinesh, M. S.; Dekker, Andre; More. …Drug-related pneumonitis as a result of novel cancer therapy provides new challenges for providers of cancer care in the era of precision medicine. Awareness of this emerging entity and knowledge of its manifestations and management guidelines are essential for state-of-the-art practice of clinical oncology. Here, we provide a detailed …DOI: 10.1200/PO.21.00108 JCO Precision Oncology no. 5 (2021) 1151-1159. Published online July 15, 2021. Published online July 15, 2021. Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-AnalysisThe Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ...JCO Precision Oncology, published online May 14, 2018. https://ascopubs.org/doi/full/10.1200/PO.17.00247. Thyroid Cancer. Busaidy NL, Konda B, Wei L, Wirth LJ ...DOI: 10.1200/PO.22.00715 JCO Precision Oncology no. 7 (2023) e2200715. Published online June 7, 2023. PMID: 37285561. Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer Sarah N. Gibbs, MPH 1. x. Sarah N. Gibbs. Search for articles by this author ...WebSep 22, 2023 · Acknowledgment of Reviewers, 2023. Peer review is at the core of scientific progress. It is through the careful critique of peer reviewers that manuscripts are scrutinized, evaluated, and improved. An article that has been peer reviewed is determined to be valid and worthy of publication. These peer-reviewed manuscripts are a critical component ... A precision haircut is a style using techniques that create straight, dramatic lines and clean angles. Vidal Sassoon was the pioneer of precision haircutting, with the original philosophy of creating haircuts based on a client’s bone struct...DOI: 10.1200/PO.21.00181 JCO Precision Oncology no. 6 (2022) e2100181. Published online March 9, 2022. PMID: 35263168. Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors Pashtoon M. Kasi, MD, MS 1. x. Pashtoon M. Kasi. Search for articles by …Web

PURPOSE We conducted this systematic review to evaluate the clinical outcomes associated with molecular tumor board (MTB) review in patients with cancer. METHODS A systematic search of PubMed was performed to identify studies reporting clinical outcomes in patients with cancer who were reviewed by an MTB. To be included, studies had to report clinical outcomes, including clinical benefit ...

DOI: 10.1200/PO.23.00261 JCO Precision Oncology no. 7 (2023) e2300261. Published online October 12, 2023. PMID: 37824797. Computational Advancements in Cancer Combination Therapy Prediction Victoria L. Flanary, BS 1. x. Victoria L. Flanary. Search for articles by this author ...

The field of behavioral economics recognizes that humans make decisions within the constraints of bounded rationality because of time and cognitive limits such as those observed with precision oncology. 1 This results in the use of heuristics (such as race), which may in turn increase individuals' reliance on cognitive biases (including …Supported by The Cholangiocarcinoma Foundation (to M.Y.), the National Cancer Institute Specialized Program of Research Excellence (SPORE) in Gastrointestinal Cancers (P50 CA062924), the NIH Center Core Grant (P30 CA006973), and the American Society of Clinical Oncology Career Development Award.This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: …DOI: 10.1200/PO.17.00084 JCO Precision Oncology - published online October 3, 2017The Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ...DOI: 10.1200/PO.19.00333 JCO Precision Oncology no. 4 (2020) 411-425. Published online April 23, 2020. PMID: 35050738. Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review Jing Zhao, MD 1. x. Jing Zhao. Search for articles by this author. and Yang ...WebJCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer.PURPOSE Next-generation sequencing (NGS) of tumor and germline DNA is foundational for precision oncology, with rapidly expanding diagnostic, prognostic, and therapeutic implications. Although few question the importance of NGS in modern oncology care, the process of gathering primary molecular data, integrating it into electronic health …DOI: 10.1200/PO.19.00154 JCO Precision Oncology no. 4 (2020) 6-19. Published online January 7, 2020. PMID: 35050726. International Harmonization of Provisional Diagnostic Criteria for ...This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: RocheJCO Precision Oncology. Published by American Society of Clinical Oncology. Online ISSN: 2473-4284. Top-cited authors. Debyani Chakravarty. Memorial Sloan Kettering …

DOI: 10.1200/PO.22.00621 JCO Precision Oncology no. 7 (2023) e2200621. Published online February 21, 2023. Published online February 21, 2023. Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRAS G12C -Mutant Non–Small-Cell Lung CancerAs significant efforts in distinct geographical areas are underway to enhance the clinical impact of precision oncology, several challenges remain. First, the type of tumor sample used can affect the results of genomic assays and have downstream effects on therapeutic decisions. In a study comparing mutation calls from whole-exome sequencing in ...PURPOSE HER2 is a critical gene that drives various solid tumors in addition to those of breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC). Overexpression, amplification, and point mutations in HER2 have been described in patients with NSCLC; however, the potential roles of these alterations remain unclear. METHODS We summarize the evidence regarding the ...DOI: 10.1200/PO.21.00267 JCO Precision Oncology no. 6 (2022) e2100267. Published online February 2, 2022. PMID: 35108036. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers Benjamin Garmezy, MD 1. x ...Instagram:https://instagram. carnival cruise stock prices todaymarathon digital stock forecastuniversal health sharecheapest motorcycle insurance in california This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: RochePURPOSE HER2-altered non–small-cell lung cancer (NSCLC) represents a diverse subgroup, including mutations, amplifications, and overexpression. However, HER2 exon 20 insertion mutations are emerging as a distinct molecular subtype with expanding therapeutic options. We describe the molecular epidemiology and genomic features of …Web should i buy target stock right nowus forex trading brokers By choosing this option you are agreeing to pay the article processing charge of $2,300 (Original Reports) or $792 (Case Reports). This will be billed after acceptance of your article. Open access requirements may vary depending on the source of funding for your submission. If you have questions regarding open access requirements, this guide to ... From Race-Based to Precision Oncology: Leveraging Behavioral Economics and the Electronic Health Record to Advance Health Equity in Cancer Care Lau-Min et al. Published online: February 17, 2021 vo2 apple watch Jan 1, 2020 · JCO PO publishes controlled randomized clinical trials and other comparative studies in precision oncology. For randomized clinical trials and other comparative studies, authors should carefully follow the ICMJE and CONSORT statement guidelines. To produce consistent results, please refer to JCO PO 's CONSORT template. Jun 27, 2017 · Purpose Multiple-gene, next-generation sequencing panels are increasingly used to assess hereditary cancer risks of patients with diverse personal and family cancer histories. The magnitude of breast and ovarian cancer risk associated with many clinically tested genes, and independent of family cancer history, remains to be quantified. Methods We queried a commercial laboratory database of ...